Anti hypertensive Drugs

  • Chemical Composition

    Candesartan Cilexetil 16 mg

  • Packing


  • Medical Id


  • License Number


  • License date


Mechanism Of Action Candesartan cilexetil is a prodrug, it is hydrolyzed to candesartan during absorption from the gastrointestinal tract. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland.
INDICATIONS Hypertension: Candesartan-kanawati is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. Heart Failure: Candesartan-kanawati is indicated for the treatment of heart failure in patients with left ventricular systolic dysfunction. Candesartan-kanawati also has an added effect on these outcomes when used with an ACE inhibitor
CONTRAINDICATIONS Candesartan-kanawati is contraindicated in patients who are hypersensitive to any component of this product.
Side EFFECTS The most adverse effects include dizziness, headache, sore throat, runny nose, and blurred vision, these side effects disappear as the body adjusts to the medication. Tell your doctor immediately if any of these rare but very serious side effects occur: change in the amount of urine, stomach/abdominal pain, persistent nausea/vomiting, yellowing eyes or skin, dark urine, unusual tiredness, muscle pain. Allergic reactions may very rarely occur, symptoms of a serious allergic reaction may include: rash, itching, swelling (especially of the face, lips, tongue, or throat), severe dizziness, trouble breathing.
WARNINGS Drugs that act directly on the renin-angiotensin system can cause fetal and neonatal morbidity and death when administered to pregnant women. When pregnancy is detected, Candesartan-kanawati should be discontinued as soon as possible. In patients with an activated renin-angiotensin system, such as those being treated with diuretics, symptomatic hypotension may occur. These conditions should be corrected prior to administration of Candesartan-kanawati , or the treatment should start under close medical supervision. If hypotension occurs, the patients should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment which usually can be continued without difficulty once the blood pressure has stabilized. Caution should be observed when initiating therapy in patients with heart failure. Patients with heart failure given Candesartan-kanawati commonly have some reduction in blood pressure. In patients with symptomatic hypotension this may require temporarily reducing the dose of Candesartan-kanawati , or diuretic, or both, and volume repletion. Monitoring of blood pressure is recommended during dose escalation and periodically thereafter. Caution should be exercised when using Candesartan-kanawati in patients with kidney and liver diseases, and patients having surgery. In addition, caution should be exercised when using Candesartan-kanawati in patients with high blood levels of potassium, heart problems, severe dehydration (loss of electrolytes such as sodium), or diabetes (poorly controlled). This drug may cause dizziness; use caution when driving or using machinery. Limit alcoholic beverages. Caution is advised when using this drug in the elderly because they may be more sensitive to the effects of the drug, especially the dizziness effect.
DRUG INTERACTIONS : An increase in serum lithium concentration has been reported during concomitant administration of lithium with Candesartan Silexetil, so careful monitoring of serum lithium levels is recommended during concomitant use. Hyperkalemia may occur, when Candesartan-kanawati is taken concomitantly with ACE inhibitors and potassium-sparing diuretics such as spironolactone.
Pregnancy And lactations Pregnancy: This medication should be used only when clearly needed during the first three months of pregnancy (Categories C). It is not recommended for use during the last six months of the pregnancy due to the risk for fetal harm (Category D). Nursing Mothers: Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Dosage And Administration Hypertension: The usual recommended starting dose of Candesartan-kanawati is 16 mg once daily when it is used as monotherapy. Candesartan-kanawati can be administered once or twice daily with total daily doses ranging from 8 mg to 32 mg. Most of the antihypertensive effect is present within 2 weeks, and maximal blood pressure reduction is generally obtained within 4 to 6 weeks of treatment with Candesartan Silexetil. In patients with moderate hepatic impairment, consideration should be given to initiation of Candesartan-kanawati at a lower dose. For patients with possible depletion of intravascular volume (eg, patients treated with diuretics, particularly those with impaired renal function), Candesartan-kanawati should be initiated under close medical supervision and consideration should be given to administration of a lower dose. Candesartan-kanawati may be administered with or without food. If blood pressure is not controlled by Candesartan-kanawati alone, a diuretic may be added. Candesartan-kanawati may be administered with other antihypertensive agents. Heart Failure: The recommended initial dose for treating heart failure is 4 mg once daily. The target dose is 32 mg once daily, which is achieved by doubling the dose at approximately 2-week intervals, as tolerated by the patient.
Storage Conditions Store below 25°C. Keep out of reach of children.